Retatrutide Research Overview: The Triple Agonist in the Published Literature
Retatrutide (LY3437943) is an unapproved compound under active study in metabolic research. Its mechanism and early evidence are published, but phase 3 results are not, and several questions remain open.
Mechanism: engineered triple agonism
Retatrutide is a 39-amino-acid synthetic peptide built on a GIP backbone, with a C20 fatty-diacid for albumin binding. It activates three receptors at once: GIP, GLP-1 and glucagon. The activity ratio is deliberate: strongest at GIP, moderate at glucagon, and attenuated at GLP-1 relative to the native hormones. The design hypothesis is that GLP-1/GIP suppress intake and improve insulin dynamics, while glucagon adds an energy-expenditure and hepatic fat-oxidation component the other incretins lack.
The published evidence
- Phase 1 established once-weekly pharmacokinetics and tolerability consistent with the incretin class.
- Phase 2 (NEJM, 2023) reported mean weight reduction of ~24% at 48 weeks at the highest dose, without plateau at study end. Adverse events were predominantly gastrointestinal, consistent with class effects.
- Liver-fat sub-study: over 80% of participants with fatty liver at baseline reached normal liver-fat content at the top doses. The result has driven substantial hepatology interest.
- Phase 3 (TRIUMPH program) is ongoing across obesity, diabetes, and obstructive sleep apnea populations; no phase 3 results have published yet.
Open research questions
Current literature focuses on three questions: whether glucagon-driven energy expenditure holds up against compensatory intake in large populations; the heart-rate elevation observed at higher doses; and lean-mass preservation during rapid weight loss. Each remains an active in-vitro and preclinical research area. Receptor-level signaling studies of the triple agonism are still being mapped.
Laboratory notes
Handle as a large lipidated peptide: reconstitute gently in bacteriostatic water, refrigerate at 2–8°C, protect from light, and never shake or freeze the solution (see stability windows). Confirm batch identity by mass spec on the certificate of analysis.
We stock independently tested retatrutide in 10mg, 20mg, 40mg, 50mg and 60mg vials; for comparative work see the dual-vs-triple comparison. For research use only — not for human or veterinary use.